Validation of the leukocyte labeling procedure with a new kit for the preparation of technetium-99m exametazime injection. Issue 4 (April 2016)

• Record Type: Journal Article
• Authors: Martinez, Teresa; Gallego Peinado, Marta; Sanchez Catalicio, Jose; Perez Angel, Florentina; Contreras Gutiérrez, Jose
• Is Part Of: Nuclear medicine communications. Volume 37:Issue 4(2016:Apr.)
• Publication Date: 2016-04
• Subjects: exametazime -- HMPAO -- labeling -- leukocyte -- validation; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000000458
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : The labeling of leukocytes with technetium-99m ( 99m Tc)-HMPAO is a frequent procedure in our laboratory, which was first validated before initiation of clinical studies with the commercial kit of 99m Tc-D, L-hexamethylpropylene amine oxime ( 99m Tc-D, L-HMPAO), available from 1988. Recently, a new kit of exametazime has been introduced, with a similar composition and clinical indications, but with some technical improvements. Validation of the labeling procedure with this new kit is proposed, including a comparison between both commercial kits. Requirements for validation were achieved successfully and a comparative study showed no statistically significant differences; nevertheless, labeling of leukocytes may be expected routinely with the new kit on account of its longer shelf-life and lower cost.